

Joachim Burman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5767484/publications.pdf>

Version: 2024-02-01

76
papers

3,357
citations

201674

27
h-index

155660

55
g-index

79
all docs

79
docs citations

79
times ranked

4498
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	9.0	455
2	Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurology, 2020, 77, 184.	9.0	342
3	CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. Journal of Neuroinflammation, 2012, 9, 112.	7.2	243
4	Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 165.	7.4	208
5	Association of Nonmyeloablative Hematopoietic Stem Cell Transplantation With Neurological Disability in Patients With Relapsing-Remitting Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2015, 313, 275.	7.4	164
6	Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Advances, 2017, 1, 2742-2755.	5.2	151
7	Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1116-1121.	1.9	139
8	Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplantation, 2020, 55, 283-306.	2.4	128
9	Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Annals of Neurology, 2020, 87, 688-699.	5.3	86
10	Assessing tissue damage in multiple sclerosis: a biomarker approach. Acta Neurologica Scandinavica, 2014, 130, 81-89.	2.1	67
11	YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. Journal of Neuroimmunology, 2016, 292, 52-57.	2.3	64
12	Epilepsy in multiple sclerosis. Neurology, 2017, 89, 2462-2468.	1.1	57
13	Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society. Acta Neurologica Scandinavica, 2017, 135, 17-24.	2.1	57
14	Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party. Multiple Sclerosis Journal, 2015, 21, 189-197.	3.0	56
15	Autologous haematopoietic stem cell transplantation for neurological diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 147-155.	1.9	52
16	Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurology, The, 2022, 21, 693-703.	10.2	45
17	Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?. Acta Neurologica Scandinavica, 2018, 138, 327-331.	2.1	43
18	Bilateral and recurrent optic neuritis in multiple sclerosis. Acta Neurologica Scandinavica, 2011, 123, 207-210.	2.1	41

#	ARTICLE	IF	CITATIONS
19	Intranasal delivery of central nervous systemâ€targeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis. <i>Immunology</i> , 2014, 142, 431-441.	4.4	41
20	Integration of magnetic resonance imaging and protein and metabolite CSF measurements to enable early diagnosis of secondary progressive multiple sclerosis. <i>Theranostics</i> , 2018, 8, 4477-4490.	10.0	39
21	Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP). <i>Bone Marrow Transplantation</i> , 2015, 50, 216-220.	2.4	38
22	Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. <i>Reviews in the Neurosciences</i> , 2021, 32, 573-595.	2.9	38
23	Container-based bioinformatics with Pachyderm. <i>Bioinformatics</i> , 2019, 35, 839-846.	4.1	35
24	Biochemical Differences in Cerebrospinal Fluid between Secondary Progressive and Relapsingâ€Remitting Multiple Sclerosis. <i>Cells</i> , 2019, 8, 84.	4.1	35
25	Tâ€cell responses after haematopoietic stem cell transplantation for aggressive relapsingâ€remitting multiple sclerosis. <i>Immunology</i> , 2013, 140, 211-219.	4.4	32
26	Intrathecal treatment trial of rituximab in progressive MS. <i>Neurology</i> , 2018, 91, e1893-e1901.	1.1	32
27	T regulatory cells lacking CD25 are increased in MS during relapse. <i>Autoimmunity</i> , 2010, 43, 590-597.	2.6	30
28	Alterations in the tyrosine and phenylalanine pathways revealed by biochemical profiling in cerebrospinal fluid of Huntingtonâ€™s disease subjects. <i>Scientific Reports</i> , 2019, 9, 4129.	3.3	30
29	Risk of epilepsy after a single seizure in multiple sclerosis. <i>European Journal of Neurology</i> , 2018, 25, 854-860.	3.3	27
30	Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. <i>Bone Marrow Transplantation</i> , 2021, 56, 1493-1508.	2.4	27
31	The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention. <i>Journal of Neuroimmunology</i> , 2014, 277, 153-159.	2.3	26
32	Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016, 292, 40-44.	2.3	26
33	Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 12, 82-87.	2.0	26
34	Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsingâ€remitting multiple sclerosis: an observational study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 189-194.	1.9	25
35	Autologous hematopoietic stem cell transplantation for multiple sclerosis â€ if confused or hesitant, remember: â€Treat with standard immune suppressive drugs and if no inflammation, no responseâ€™. <i>Multiple Sclerosis Journal</i> , 2012, 18, 772-775.	3.0	23
36	Interoperable and scalable data analysis with microservices: applications in metabolomics. <i>Bioinformatics</i> , 2019, 35, 3752-3760.	4.1	22

#	ARTICLE	IF	CITATIONS
37	Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with “aggressive” multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1198-1204.	3.0	22
38	Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease. <i>PLoS ONE</i> , 2018, 13, e0193492.	2.5	21
39	Normal outcome of pregnancy with ongoing treatment with natalizumab. <i>Acta Neurologica Scandinavica</i> , 2014, 129, e27-e29.	2.1	20
40	A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1. <i>Clinical Neuropharmacology</i> , 2015, 38, 170-176.	0.7	20
41	Treatment of epilepsy in multiple sclerosis. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2018, 58, 47-51.	2.0	20
42	Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab. <i>JAMA Network Open</i> , 2022, 5, e2211497.	5.9	20
43	Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 320-327.	2.1	19
44	Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2017, 52, 1133-1137.	2.4	18
45	Targeted metabolomics of CSF in healthy individuals and patients with secondary progressive multiple sclerosis using high-resolution mass spectrometry. <i>Metabolomics</i> , 2020, 16, 26.	3.0	18
46	Intrathecal immunoglobulins and neurofilament light after autologous haematopoietic stem cell transplantation for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1351-1359.	3.0	17
47	Prognostic impact of epilepsy in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101497.	2.0	17
48	Cerebral blood flow measurements with ¹⁵ O-water PET using a non-invasive machine-learning-derived arterial input function. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2229-2241.	4.3	15
49	Metabolomics of Cerebrospinal Fluid from Healthy Subjects Reveal Metabolites Associated with Ageing. <i>Metabolites</i> , 2021, 11, 126.	2.9	15
50	New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis. <i>Bone Marrow Transplantation</i> , 2021, 56, 1509-1517.	2.4	14
51	Profound but Transient Changes in the Inflammatory Milieu of the Blood During Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 50-57.	2.0	12
52	Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease. <i>Movement Disorders</i> , 2021, 36, 481-491.	3.9	12
53	Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 844-848.	1.9	11
54	Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS. <i>Fluids and Barriers of the CNS</i> , 2020, 17, 49.	5.0	10

#	ARTICLE	IF	CITATIONS
55	Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 1473-1475.	2.4	9
56	Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e1574-e1584.	1.1	9
57	Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1532-1539.	3.0	8
58	Rehabilitation Before and After Autologous Haematopoietic Stem Cell Transplantation (AHSCT) for Patients With Multiple Sclerosis (MS): Consensus Guidelines and Recommendations for Best Clinical Practice on Behalf of the Autoimmune Diseases Working Party, Nurses Group, and Patient Advocacy Committee of the European Society for Blood and Marrow Transplantation (EBMT). <i>Frontiers in Neurology</i> , 2020, 11, 556141.	2.4	8
59	Evaluation of polarity switching for untargeted lipidomics using liquid chromatography coupled to high resolution mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2022, 1195, 123200.	2.3	8
60	Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease. <i>Journal of Neuroimmunology</i> , 2019, 332, 31-36.	2.3	7
61	Serum Neurofilament Light Chain in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 0, , .	3.7	7
62	Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension. <i>Journal of Neurology</i> , 2021, 268, 651-657.	3.6	6
63	Metabolic drift in the aging nervous system is reflected in human cerebrospinal fluid. <i>Scientific Reports</i> , 2021, 11, 18822.	3.3	6
64	Intestinal Microbiome in Hematopoietic Stem Cell Transplantation For Autoimmune Diseases: Considerations and Perspectives on Behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT. <i>Frontiers in Oncology</i> , 2021, 11, 722436.	2.8	6
65	Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology. <i>Immunity, Inflammation and Disease</i> , 2022, 10, e595.	2.7	6
66	Autologous hematopoietic stem cell transplantation for MS. <i>Neurology</i> , 2017, 88, 2072-2073.	1.1	5
67	Delaying the inevitable: Are disease modifying drugs for progressive MS worthwhile?. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103134.	2.0	4
68	Autologous Hematopoietic Stem Cell Transplantation In Neuromyelitis Optica: A Retrospective Study Of The EBMT Autoimmune Diseases Working Party In Collaboration With The University Of Sao Paulo, Ribeirao Preto, Brazil. <i>Blood</i> , 2013, 122, 2125-2125.	1.4	3
69	Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2022, 198, 24-45.	2.5	3
70	Urokinase, CX3CL1, CCL2, TRAIL and IL-18 induced by interferon- γ treatment. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 602-607.	2.1	2
71	Temporal trends of epilepsy in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2022, 146, 492-498.	2.1	2
72	Quantification of $\gamma\delta$ T cells and HLA-DR+ NK cells does not predict emergence of new contrast enhancing lesions in MS patients suspending natalizumab treatment. <i>PLoS ONE</i> , 2017, 12, e0179095.	2.5	1

#	ARTICLE	IF	CITATIONS
73	Retention of antiseizure medications for epilepsy in multiple sclerosis: A retrospective observational study. <i>Epilepsy and Behavior</i> , 2021, 121, 108034.	1.7	1
74	Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 275, 141.	2.3	0
75	Blogs cannot separate wheat from chaff. <i>Science</i> , 2017, 358, 602-602.	12.6	0
76	Outcome Of Pregnancy After Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Autoimmune Diseases (AD): A Retrospective Study Of The EBMT Autoimmune Diseases Working Party (ADWP). <i>Blood</i> , 2013, 122, 4640-4640.	1.4	0